Drug-eluting stent insertion in the treatment of in-stent renal artery restenosis in three renal transplant recipients.
Percutaneous transluminal angioplasty (PTA) with or without stent insertion is the treatment of choice in transplant renal artery stenosis. However, in-stent restenosis occurs in as many as 13% of patients after PTA and stent insertion. This article describes three patients with recurrent transplant renal artery in-stent stenosis who were treated with paclitaxel-eluting stents. In two patients, the transplant renal artery remained patent after insertion of the drug-eluting stent (DES), and one patient required balloon angioplasty 7 months after the DES was inserted.
Douis
Hassan
H
Department of Radiology, University Hospital Birmingham National Health Service Foundation Trust, Birmingham B15 2TH, United Kingdom.
Shabir
Shazia
S
Lipkin
Graham
G
Riley
Peter
P
D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D018810:Magnetic Resonance Angiography; D008297:Male; D008670:Metals; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011474:Prosthesis Design; D011859:Radiography; D012008:Recurrence; D012078:Renal Artery Obstruction / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D015607:Stents; D016896:Treatment Outcome; D014654:Vascular Patency
D002317:Cardiovascular Agents; D008670:Metals; D017239:Paclitaxel